- Home
- PRQR vs RLTY Comparison
PRQR vs RLTY Comparison
Compare PRQR & RLTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- RLTY
- Stock Information
- Founded
- PRQR 2012
- RLTY 2022
- Country
- PRQR Netherlands
- RLTY United States
- Employees
- PRQR N/A
- RLTY N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- RLTY Investment Managers
- Sector
- PRQR Health Care
- RLTY Finance
- Exchange
- PRQR Nasdaq
- RLTY Nasdaq
- Market Cap
- PRQR 309.5M
- RLTY 259.2M
- IPO Year
- PRQR 2014
- RLTY N/A
- Fundamental
- Price
- PRQR $1.27
- RLTY $15.09
- Analyst Decision
- PRQR Strong Buy
- RLTY
- Analyst Count
- PRQR 6
- RLTY 0
- Target Price
- PRQR $8.50
- RLTY N/A
- AVG Volume (30 Days)
- PRQR 694.9K
- RLTY 86.7K
- Earning Date
- PRQR 03-13-2025
- RLTY 01-01-0001
- Dividend Yield
- PRQR N/A
- RLTY 9.35%
- EPS Growth
- PRQR N/A
- RLTY N/A
- EPS
- PRQR N/A
- RLTY N/A
- Revenue
- PRQR $20,235,014.00
- RLTY N/A
- Revenue This Year
- PRQR $39.44
- RLTY N/A
- Revenue Next Year
- PRQR N/A
- RLTY N/A
- P/E Ratio
- PRQR N/A
- RLTY N/A
- Revenue Growth
- PRQR 196.41
- RLTY N/A
- 52 Week Low
- PRQR $1.25
- RLTY $11.38
- 52 Week High
- PRQR $4.62
- RLTY $14.60
- Technical
- Relative Strength Index (RSI)
- PRQR 22.66
- RLTY 41.01
- Support Level
- PRQR $1.25
- RLTY $15.15
- Resistance Level
- PRQR $1.39
- RLTY $15.54
- Average True Range (ATR)
- PRQR 0.09
- RLTY 0.28
- MACD
- PRQR -0.01
- RLTY -0.01
- Stochastic Oscillator
- PRQR 3.92
- RLTY 10.81
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
About RLTY Cohen & Steers Real Estate Opportunities and Income Fund of Beneficial Interest
Cohen & Steers Real Estate Opportunities and Income Fund is an organized, non-diversified, closed-end management investment company. The Fund's primary investment objective is high current income. The Fund's secondary investment objective is capital appreciation.